References
- Kaipia A, Riikonen J. Contemporary and past challenges of prostate cancer diagnostics. Scand J Urol. 2017;51(3):193–201.
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282.
- Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
- Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
- Tucci M, Bertaglia V, Vignani F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):563–573.
- Levit LA, Byatt L, Lyss AP, et al. Closing the rural cancer care gap: three institutional approaches. JCO Oncol Pract. 2020;16(7):422–430.
- Charlton M, Schlichting J, Chioreso C, et al. Challenges of rural cancer care in the United States. Oncology. 2015;29(9):633–640.
- Baade PD, Yu XQ, Smith DP, et al. Geographic disparities in prostate cancer outcomes-review of international patterns. Asian Pac J Cancer Prev. 2015;16(3):1259–1275.
- Nieder C, Dalhaug A, Haukland E. Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting. Scand J Urol. 2020;54(2):110–114.
- Azad AA, Tran B, Davis ID, et al. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Intern Med J. 2021. doi: https://doi.org/10.1111/imj.15288.
- Rulach RJ, McKay S, Neilson S, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. 2018;121(2):268–274.
- James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
- Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and Meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. Erratum in: Lancet Oncol. 2016;17:e46.
- Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.
- Adashek JJ, Reed JP, Tandon A, et al. Combination androgen receptor inhibition and docetaxel in metastatic castration-sensitive prostate cancer: the next step in first-line treatment? Clin Genitourin Cancer. 2020;18(6):425–428.
- Vigneswaran HT, Warnqvist A, Andersson TML, et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scand J Urol. 2021;55(4):299–306.